Mesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitors

International Journal of Oncology

Volumn 39, Issue 3, 2011, Pages 689-696

  Dittmer, Angela ^a   Fuchs, Alexander ^b   Oerlecke, Ilka ^a   Leyh, Benjamin ^a   Kaiser, Susann ^b   Martens, John W M ^c   Lützkendorf, Jana ^a   Müller, Lutz ^a   Dittmer, Jürgen ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; CAFs; ERK1 2; Ets1; MSCs; Raf inhibitor

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CHIR 265; DOVITINIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C ALPHA; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

BREAST NEOPLASMS; CELL COMMUNICATION; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; FIBROBLASTS; HUMANS; IMIDAZOLES; MESENCHYMAL STEM CELLS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; RAF KINASES; SIROLIMUS; STROMAL CELLS; TOR SERINE-THREONINE KINASES;

EID: 79959955162     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1073     Document Type: Article

References (57)

1. Tlsty TD and Coussens LM: Tumor stroma and regulation of cancer development. Annu Rev Pathol 1: 119-150, 2006.
2. Kim JB, Stein R and O'Hare MJ: Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol 26: 173-185, 2005. (Pubitemid 41379743)
3. Wiseman BS and Werb Z: Stromal effects on mammary gland development and breast cancer. Science 296: 1046-1049, 2002. (Pubitemid 34517108)
4. Mueller MM and Fusenig NE: Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4: 839-849, 2004. (Pubitemid 39472951)
5. Dittmer J: Mesenchymal stem cells and their role in tumor progression. In: Cancer Stem Cells. Jordan ME (ed). Nova Publisher, New York, NY, pp61-75, 2010.
6. Kidd S, Spaeth E, Klopp A, Andreeff M, Hall B and Marini FC: The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy 10: 657-667, 2008.
7. Yen L and Yen M-L: Mesenchymal stem cells and cancer - for better or for worse? J Cancer Molecules 4 5-9, 2008.
8. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R Keating A, Prockop D and Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317, 2006.
9. Uccelli A, Moretta L and Pistoia V: Mesenchymal stem cells in health and disease. Nat Rev Immunol 8: 726-736, 2008.
10. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, Liles WC and Stewart DJ: Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 182: 1047-1057, 2010.
11. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J and Brigham KL: Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 33: 145-152, 2005. (Pubitemid 41473051)
12. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M and Lang FF: Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65: 3307-3318, 2005. (Pubitemid 40524615)
13. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62: 3603-3608, 2002. (Pubitemid 34728832)
14. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R and Weinberg RA: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563, 2007. (Pubitemid 47525152)
15. Dittmer A, Hohlfeld K, Lutzkendorf J, Muller LP and Dittmer J: Human mesenchymal stem cells induce E-cadherin degradation in breast carcinoma spheroids by activating ADAM10. Cell Mol Life Sci 66: 3053-3065, 2009.
16. Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW and Banerjee D: Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 68: 4331-4339, 2008.
17. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M and Marini F: Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4 e4992, 2009.
18. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J and Ferrara N: PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15: 21-34, 2009.
19. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R and Olsen BR: Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 16: 1400-1406, 2010.
20. Gilbert LA and Hemann MT: DNA damage-mediated induction of a chemoresistant niche. Cell 143: 355-366, 2010.
21. Lemmon MA and Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134, 2010.
22. Prat A and Perou CM: Mammary development meets cancer genomics. Nat Med 15: 842-844, 2009.
23. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D and Bertucci F: Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25: 2273-2284, 2006.
24. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, De Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SR Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW and Schutte M: Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 121: 53-64, 2009.
25. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
26. Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ and Hynes NE: Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 70: 4151-4162, 2010.
27. Moreira C and Kaklamani V: Lapatinib and breast cancer: current indications and outlook for the future. Expert Rev Anticancer Ther 10: 1171-1182, 2010.
28. Di Cosimo S and Baselga J: Targeted therapies in breast cancer: where are we now? Eur J Cancer 44: 2781-2790, 2008.
29. Georgakis GV and Younes A: From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev Anticancer Ther 6: 131-140, 2006.
30. Zitzmann K, Ruden J, Brand S, Goke B, Lichtl J, Spottl G and Auernhammer CJ: Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 295: 100-109, 2010.
31. Mordant P, Loriot Y, Leteur C, Calderaro J, Bourhis J, Wislez M, Soria JC and Deutsch E Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther 9: 358-368, 2010.
32. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW and Korn WM: Basal subtype and MAPK/ ERK kinase (MEK)- phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69: 565-572, 2009.
33. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D and Sliwkowski MX: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15: 429-440, 2009
34. Pampaloni F, Reynaud EG and Stelzer EH: The third dimension bridges the gap between cell culture and live tissue Nat Rev Mol Cell Biol 8: 839-845, 2007.
35. Martens JW, Sieuwerts AM, Bolt-deVries J, Bosma PT, Swiggers SJ, Klijn JG and Foekens JA: Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. Thromb Haemost 89: 393-404, 2003. (Pubitemid 36227292)
36. Dittmer A, Schunke D and Dittmer J: PTHrP promotes homotypic aggregation of breast cancer cells in three-dimensional cultures. Cancer Lett 260: 56-61, 2008.
37. Dittmer A, Vetter M, Schunke D, Span PN, Sweep F, Thomssen C and Dittmer J: Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells. J Biol Chem 281: 14563-14572, 2006. (Pubitemid 43855159)
38. Vetter M, Blumenthal SG, Lindemann RK, Manns J, Wesselborg S, Thomssen C and Dittmer J: Etsl is an effector of protein kinase Calpha in cancer cells. Oncogene 24 650-661, 2005. (Pubitemid 40188569)
39. Yang BS, Hauser CA, Henkel G, Colman MS, van Beveren C, Stacey KJ, Hume DA, Maki RA and Ostrowski MC: Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Etsl and c-Ets2. Mol Cell Biol 16: 538-547, 1996. (Pubitemid 26029092)
40. Dittmer J: The biology of the Etsl proto-oncogene. Mol Cancer 2: 29, 2003.
41. Kars MD, Iseri OD and Gunduz U: Drug resistant breast cancer cells overexpress ETSl gene. Biomed Pharmacother 64 458-462, 2010.
42. Lindemann RK, Braig M, Ballschmieter P, Guise TA, Nordheim A and Dittmer J: Protein kinase Calpha regulates Etsl transcriptional activity in invasive breast cancer cells. Int J Oncol 22: 799-805, 2003.
43. Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, Li L, Spaeth E, Xu W, Zhang X, Lewis MT, Reuben JM, Krishnamurthy S, Ferrari M, Caspar R Buchholz TA, Cristofanilli M, Marini F, Andreeff M and Woodward WA: Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS 5: e12180, 2010.
44. Parekkadan B, van Poll D, Suganuma K, Carter EA, Berthiaume F, Tilles AW and Yarmush ML: Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS One 2: e941, 2007.
45. Hazlehurst LA and Dalton WS: Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev 20: 43-50, 2001. (Pubitemid 34074677)
46. Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, Ottonello L and Pistoia V: Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26: 151-162, 2008.
47. Prat A and Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 5: 5-23, 2011.
48. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW and Schutte M: Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 5: 195-201, 2007. (Pubitemid 46424000)
49. Liu J, Stevens PD and Gao T: mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J Biol Chem 286: 6510-6520, 2011.
50. Poulikakos PI, Zhang C, Bollag G, Shokat KM and Rosen N RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464 427-430, 2010.
51. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KR Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS and Malek S: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464: 431-435, 2010.
52. Heidorn SJ, Milagre C, Whittaker S, Nourry A, NiculescuDuvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C and Marais R: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 140: 209-221, 2010.
53. Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT and Smalley KS: Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 102: 1724-1730, 2010.
54. Timoshenko AV, Rastogi S and Lala PK: Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. Br J Cancer 97: 1090-1098, 2007. (Pubitemid 47587011)
55. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A and Asada M: Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14: 5459-5465, 2008.
56. Samoszuk M, Tan J and Chorn G: Clonogenic growth of human breast cancer cells co-cultured in direct contact with serum-activated fibroblasts. Breast Cancer Res 7: R274-R283, 2005.
57. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R and Delorenzi M: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15: 68-74, 2009.